Mark Newcomer Sells 12,000 Shares of Paysign, Inc. (NASDAQ:PAYS) Stock

Paysign, Inc. (NASDAQ:PAYS) CEO Mark Newcomer sold 12,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $2.85, for a total transaction of $34,200.00. Following the transaction, the chief executive officer now directly owns 9,036,886 shares of the company’s stock, valued at $25,755,125.10. This represents a 0.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Mark Newcomer also recently made the following trade(s):

• On Tuesday, January 21st, Mark Newcomer sold 61,000 shares of Paysign stock. The stock was sold at an average price of $2.89, for a total transaction of $176,290.00.
• On Monday, December 9th, Mark Newcomer sold 41,000 shares of Paysign stock. The shares were sold at an average price of $3.31, for a total transaction of $135,710.00.
• On Wednesday, November 20th, Mark Newcomer sold 25,000 shares of Paysign stock. The shares were sold at an average price of $3.27, for a total value of $81,750.00.
• On Monday, November 18th, Mark Newcomer sold 40,000 shares of Paysign stock. The stock was sold at an average price of $3.24, for a total transaction of $129,600.00.

Paysign Stock Performance

Paysign stock opened at $2.87 on Friday. The company’s fifty day moving average price is $3.14 and its 200 day moving average price is $3.90. The stock has a market capitalization of $153.69 million, a P/E ratio of 19.13 and a beta of 0.95. Paysign, Inc. has a 1 year low of $2.70 and a 1 year high of $5.59.

Paysign (NASDAQ:PAYS) last released its earnings results on Tuesday, November 5th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.02. The business had revenue of $15.26 million during the quarter, compared to analysts’ expectations of $14.96 million. Paysign had a net margin of 14.28% and a return on equity of 30.64%. During the same quarter in the previous year, the company earned $0.02 earnings per share. Sell-side analysts predict that Paysign, Inc. will post 0.21 EPS for the current year.

Hedge Funds Weigh In On Paysign

Hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its holdings in Paysign by 25.0% in the 2nd quarter. Renaissance Technologies LLC now owns 1,504,380 shares of the company’s stock valued at $6,484,000 after purchasing an additional 301,000 shares in the last quarter. Royce & Associates LP acquired a new position in Paysign during the third quarter worth about $814,000. Barclays PLC grew its stake in Paysign by 327.4% during the 3rd quarter. Barclays PLC now owns 47,090 shares of the company’s stock valued at $173,000 after acquiring an additional 36,071 shares in the last quarter. Rhumbline Advisers raised its holdings in Paysign by 25.1% in the 2nd quarter. Rhumbline Advisers now owns 35,835 shares of the company’s stock valued at $154,000 after acquiring an additional 7,190 shares during the last quarter. Finally, Joule Financial LLC purchased a new position in Paysign in the 3rd quarter worth approximately $1,478,000. Hedge funds and other institutional investors own 25.89% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on PAYS shares. Lake Street Capital started coverage on shares of Paysign in a report on Friday, December 20th. They set a “buy” rating and a $6.00 price target on the stock. Barrington Research restated an “outperform” rating and set a $7.00 target price on shares of Paysign in a research report on Monday, November 4th.

Paysign Company Profile

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.